Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$7.95 -2.3%	$9.54	$6.01 ▼ $11.31	$1.70B	1.1	2.99 million shs	7.97 million shs
HALO Halozyme Therapeutics	$59.02 -1.6%	$55.30	$42.01 ▼ $70.50	$7.39B	1.17	1.28 million shs	1.68 million shs
IONS Ionis Pharmaceuticals	$43.03 +0.1%	$39.07	$23.95 ▼ $50.43	$6.85B	0.25	1.75 million shs	2.32 million shs
RGEN Repligen	$118.91 +1.6%	$123.39	$102.96 ▼ $182.52	$6.58B	1.05	948,438 shs	941,488 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-2.33%	-7.02%	-11.86%	-10.97%	+9.20%
HALO Halozyme Therapeutics	-1.58%	+1.34%	+9.62%	-3.55%	+6.80%
IONS Ionis Pharmaceuticals	+0.12%	+1.87%	-1.28%	+31.27%	-13.00%
RGEN Repligen	+1.57%	-2.32%	-6.34%	-15.97%	-28.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.2533 of 5 stars	4.5	2.0	4.2	1.5	1.7	0.6
HALO Halozyme Therapeutics	4.728 of 5 stars	2.1	4.0	4.4	2.3	2.5	4.4
IONS Ionis Pharmaceuticals	4.5202 of 5 stars	4.4	3.0	3.0	3.2	2.5	0.6
RGEN Repligen	4.6866 of 5 stars	4.3	3.0	4.5	1.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	110.06% Upside
HALO Halozyme Therapeutics	2.17	Hold	$62.70	6.24% Upside
IONS Ionis Pharmaceuticals	2.86	Moderate Buy	$59.38	38.01% Upside
RGEN Repligen	2.67	Moderate Buy	$169.45	42.51% Upside

Current Analyst Ratings Breakdown

Latest BCRX, HALO, IONS, and RGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$60.00 ➝ $64.00
7/31/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $65.00
7/31/2025	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $62.00
7/30/2025	RGEN Repligen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$193.00 ➝ $204.00
7/30/2025	RGEN Repligen	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$180.00 ➝ $175.00
7/22/2025	RGEN Repligen	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight	$160.00
7/16/2025	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$58.00 ➝ $60.00
7/10/2025	HALO Halozyme Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$55.00
7/8/2025	RGEN Repligen	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$140.00 ➝ $130.00
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.69	N/A	N/A	($2.30) per share	-3.46
HALO Halozyme Therapeutics	$1.02B	7.16	$4.58 per share	12.89	$2.86 per share	20.64
IONS Ionis Pharmaceuticals	$705M	9.73	N/A	N/A	$3.96 per share	10.87
RGEN Repligen	$634.44M	10.53	$3.16 per share	37.68	$35.21 per share	3.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	1.33	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
HALO Halozyme Therapeutics	$444.09M	$3.76	15.70	9.49	0.40	44.76%	136.91%	26.05%	8/5/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-28.25%	-45.29%	-8.99%	N/A
RGEN Repligen	-$25.51M	-$0.45	N/A	50.39	2.15	-2.05%	4.65%	3.26%	N/A

Latest BCRX, HALO, IONS, and RGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	HALO Halozyme Therapeutics	$1.22	N/A	N/A	N/A	$282.66 million	N/A
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.02	N/A	N/A	N/A	$149.59 million	N/A
7/30/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	$0.70	+$0.51	$0.70	$270.90 million	$452.00 million
7/29/2025	Q2 2025	RGEN Repligen	$0.40	$0.37	-$0.03	$0.26	$174.62 million	$182.37 million
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
HALO Halozyme Therapeutics	3.13	8.39	7.30
IONS Ionis Pharmaceuticals	0.99	2.87	9.62
RGEN Repligen	0.27	6.79	5.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
HALO Halozyme Therapeutics	97.79%
IONS Ionis Pharmaceuticals	93.86%
RGEN Repligen	97.64%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
HALO Halozyme Therapeutics	2.40%
IONS Ionis Pharmaceuticals	2.60%
RGEN Repligen	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.26 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.39 million	155.02 million	Optionable
RGEN Repligen	1,778	56.18 million	55.51 million	Optionable

BCRX, HALO, IONS, and RGEN Headlines

Recent News About These Companies

What is Leerink Partnrs' Forecast for Repligen Q3 Earnings?

1 hour ago | americanbankingnews.com

William Blair Has Positive View of Repligen FY2025 Earnings

August 1 at 6:02 AM | marketbeat.com

Q3 Earnings Estimate for Repligen Issued By Leerink Partnrs

August 1 at 5:41 AM | marketbeat.com

XTX Topco Ltd Buys 3,295 Shares of Repligen Corporation (NASDAQ:RGEN)

August 1 at 3:05 AM | marketbeat.com

FY2025 EPS Estimates for Repligen Lifted by William Blair

August 1 at 2:15 AM | americanbankingnews.com

Repligen (NASDAQ:RGEN) Given New $204.00 Price Target at Royal Bank Of Canada

July 31 at 11:08 AM | marketbeat.com

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

July 31 at 11:06 AM | benzinga.com

Wells Fargo & Company Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price

July 31 at 10:41 AM | marketbeat.com

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

July 31 at 7:30 AM | globenewswire.com

Repligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 31 at 2:46 AM | americanbankingnews.com

Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 31 at 2:44 AM | marketbeat.com

Repligen (NASDAQ:RGEN) Shares Gap Up - Time to Buy?

July 30 at 12:50 PM | marketbeat.com

Why Repligen (RGEN) Stock Is Up Today

July 30 at 12:16 PM | msn.com

Repligen (NASDAQ:RGEN) Releases Earnings Results, Misses Expectations By $0.03 EPS

July 30 at 9:18 AM | marketbeat.com

Repligen (NASDAQ:RGEN) Issues FY 2025 Earnings Guidance

July 30 at 8:17 AM | marketbeat.com

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

July 29, 2025 | seekingalpha.com

Repligen shares surge as bioprocessing firm beats revenue expectations

July 29, 2025 | au.investing.com

Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic

July 29, 2025 | finance.yahoo.com

Repligen (RGEN) Lags Q2 Earnings Estimates

July 29, 2025 | zacks.com

Repligen’s Strong Q2 Performance and Growth Prospects Justify Buy Rating

July 29, 2025 | tipranks.com

Repligen reports mixed Q2 results; updates FY25 outlook

July 29, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Stocks to Buy Ahead of the Upcoming Earnings Season
By Chris Markoch | July 11, 2025
View 3 Stocks to Buy Ahead of the Upcoming Earnings Season
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
By Gabriel Osorio-Mazilli | July 15, 2025
View Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows
Analysts Are Upgrading These 3 Massive AI Stocks After Earnings
By Leo Miller | July 29, 2025
View Analysts Are Upgrading These 3 Massive AI Stocks After Earnings

BCRX, HALO, IONS, and RGEN Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$7.95 -0.19 (-2.33%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.06 +0.11 (+1.45%)

As of 08/1/2025 07:56 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Halozyme Therapeutics NASDAQ:HALO

$59.02 -0.95 (-1.58%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$59.02 0.00 (0.00%)

As of 08/1/2025 06:48 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Ionis Pharmaceuticals NASDAQ:IONS

$43.03 +0.05 (+0.12%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$42.98 -0.05 (-0.10%)

As of 08/1/2025 07:23 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Repligen NASDAQ:RGEN

$118.91 +1.84 (+1.57%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$118.84 -0.06 (-0.05%)

As of 08/1/2025 04:10 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time